PUBLICATIONS 2020
Nutritional support in stem cell transplantation programs: Results from a multicenter survey of nurses on behalf of the Nurses Group and Transplant Complications Working Party of the European Society for Blood and Marrow Transplantation and the Gruppo Italiano Trapianto di Midollo Osseo; Stefano Botti
Reduced Calcium Signaling Is Associated With Severe Graft-Versus-Host Disease: Results From Preclinical Models and From a Prospective EBMT Study; Katarina Riesner
Investigation and Management of Bone Mineral Density Following HCT. A Survey of Current Practice by the Transplant Complications Working Party of the European Society for Blood and Marrow Transplantation; Nina Salooja
Association of Serum Ferritin Levels Before Start of Conditioning With Mortality After alloSCT - A Prospective, Non-interventional Study of the EBMT Transplant Complications Working Party; Olaf Penack
Diagnosis and Management of Secondary HLH/MAS Following HSCT and CAR-T Cell Therapy in Adults; A Review of the Literature and a Survey of Practice Within EBMT Centres on Behalf of the Autoimmune Diseases Working Party (ADWP) and Transplant Complications Working Party (TCWP); Robert David Sandler
Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation.; Olaf Penack
Frequency of lethal central nervous system neurotoxicity in patients undergoing allogeneic stem cell transplantation: a retrospective registry analysis; Schultz-Florey CR.
How much has allogeneic stem cell transplantation-related mortality improved since the 1980s? A retrospective analysis from the EBMT.; Olaf Penack
Association of uric acid levels before start of conditioning with mortality after allogeneic hematopoietic stem cell transplantation - a prospective, non-interventional study of the EBMT Transplant Complication Working Party.; Penack O,

SUBMITTED PAPER

- Association of pre-existing comorbidities with outcome of allogeneic hematopoietic cell transplantation. A retrospective analysis from the EBMT. (Olaf Penack)

OTHER

- Joint study with IDWP on Risk Factors and Frequency of Lethal Central Nervous System Toxicity in Allogeneic Stem Cell Transplantation (C. Schulze-Florey & M. Schmidt)

COMING SOON CALL FOR PARTICIPATION & DATA COLLECTION

- Autoimmune and Inflammatory Diseases (AIID) post Allogeneic Haematopoietic Cell Transplantation (HCT): a joint retrospective study of the TCWP and ADWP (A Mekinian)

Based on a large European registry, this study aims to evaluate the incidence of AIIDs after allogeneic transplantation, factors associated with these disorders, including graft-versus-host disease, the onset and the impact of the presence of AIIDs on survival.

Primary end point:
Incidence of autoimmune and inflammatory diseases after allogeneic HSCT in adult patients

Secondary end points:
1. Correlate AIIDs occurrence to GVH types and outcome, and identify factors associated with AIIDs occurrence
2. Survival outcomes (OS, NRM and event free survival)

- Outcomes of ECP in combination with new treatment protocols in Acute and Chronic GvHD (O. Penack)

Objectives: The main objective is compare and to evaluate the safety and efficacy of patients receiving ECP and/or new treatments in acute and chronic GvHD. The secondary objectives are to evaluate the steroid tapering and sparing effects of patients treated with ECP and/or new treatments, to describe the patient characteristics of patients receiving ECP and/or new treatments, and to describe the usage, sequencing and dosage of ECP with new treatment combinations in acute and chronic GvHD

Study population: Acute GvHD patients with HSCT who have failed steroids and developed Steroid Refractory-GvHD and are treated with either ECP or/and Ruxolitinib. Patients with HSCT who have developed chronic GvHD and failed to respond to steroids (Steroid Refractory-cGvHD) and are treated with either ECP or/and Ruxolitinib or/and Irubitinib.

Recruiting period 2017-2019

Type of study: Multi-centre retrospective study

Status of the study: Currently recruiting

Study Coordinator: Jessica Lemaitre (jessica.lemaitre@ebmt.org)

- Survey on the Management of Steroid Refractory GvHD (Z. Peric)

Objectives: To evaluate the current real life clinical practice in EBMT centres concerning the management of steroid-refractory acute GvHD after allo-HSCT due to hematological malignancies.

Study Coordinator: Pascale Ambron (pascale.ambron@ebmt.org)

- Graft rejection in haploidentical HSCT: survey of subsequent therapeutic options (N. Durakovitch)

Objectives: To evaluate the current real life clinical practice in EBMT centres concerning the management of graft failure after Haploidentical transplantation

Study Coordinator: Pascale Ambron (Pascale.Ambron@ebmt.org)

ABSTRACT

<table>
<thead>
<tr>
<th>EBMT 2021</th>
<th>ONGOING &amp; PLANNED ANALYSES</th>
<th>CLOSING DATA COLLECTION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Association of pre-existing co-morbidities with alloSCT outcome - a retrospective analysis (O. Penack)</td>
<td>Survey of clinical practices with the use of antithymocyte globulin (ATG) as graft-versus-host disease (GVHD) prevention(A. Plekarska)</td>
<td>EASIX to predict alloSCT outcome (O. Penack)</td>
</tr>
<tr>
<td>One thousand voices raised for patient engagement in hematopoietic stem cell transplantation and cell therapy: a context analysis from the EBMT (H. Schoemans)</td>
<td>Retrospective study on the incidence, severity, management and outcome of sinusoidal obstruction syndrome/ veno-occlusive disease of the liver (SOS/VOD) in allo HSCT in adult patients (T. Ruutu)</td>
<td>Complications of haploidentical HCT with post-transplant cyclophosphamide - a non-interventional prospective study (G. Basak)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Inclusion closed, ongoing collection of the follow-up</td>
</tr>
<tr>
<td></td>
<td></td>
<td>A cross-sectional study on the Sexual Function of Adult Survivors and their partners 3 and 15 years Post allogeneic Stem Cell Transplantation. (C. Eeltink &amp; J.Stringer)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Inclusion closed, ongoing collection of the follow-up</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Fecal microbiota transplantation in the treatment of patients after allogeneic hematopoietic stem cell transplantation (J. Bilinski)</td>
</tr>
</tbody>
</table>

www.ebmt.org